320 related articles for article (PubMed ID: 25699604)
1. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.
Wang Y; Stowe RL; Pinello CE; Tian G; Madoux F; Li D; Zhao LY; Li JL; Wang Y; Wang Y; Ma H; Hodder P; Roush WR; Liao D
Chem Biol; 2015 Feb; 22(2):273-84. PubMed ID: 25699604
[TBL] [Abstract][Full Text] [Related]
2. Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.
Li X; Wu J; Li X; Mu W; Liu X; Jin Y; Xu W; Zhang Y
Bioorg Med Chem; 2015 Oct; 23(19):6258-70. PubMed ID: 26349626
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation.
Ashwini N; Garg M; Mohan CD; Fuchs JE; Rangappa S; Anusha S; Swaroop TR; Rakesh KS; Kanojia D; Madan V; Bender A; Koeffler HP; Basappa ; Rangappa KS
Bioorg Med Chem; 2015 Sep; 23(18):6157-65. PubMed ID: 26299825
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
Lauffer BE; Mintzer R; Fong R; Mukund S; Tam C; Zilberleyb I; Flicke B; Ritscher A; Fedorowicz G; Vallero R; Ortwine DF; Gunzner J; Modrusan Z; Neumann L; Koth CM; Lupardus PJ; Kaminker JS; Heise CE; Steiner P
J Biol Chem; 2013 Sep; 288(37):26926-43. PubMed ID: 23897821
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
Raji I; Ahluwalia K; Oyelere AK
Bioorg Med Chem Lett; 2017 Feb; 27(4):744-749. PubMed ID: 28131715
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and bioevalution of novel benzamides derivatives as HDAC inhibitors.
Li Y; Zhou Y; Qian P; Wang Y; Jiang F; Yao Z; Hu W; Zhao Y; Li S
Bioorg Med Chem Lett; 2013 Jan; 23(1):179-82. PubMed ID: 23206867
[TBL] [Abstract][Full Text] [Related]
8. Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.
Xiao Y; Wang J; Zhao LY; Chen X; Zheng G; Zhang X; Liao D
Chem Commun (Camb); 2020 Aug; 56(68):9866-9869. PubMed ID: 32840532
[TBL] [Abstract][Full Text] [Related]
9. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
10. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
Feng T; Wang H; Su H; Lu H; Yu L; Zhang X; Sun H; You Q
Bioorg Med Chem; 2013 Sep; 21(17):5339-54. PubMed ID: 23820574
[TBL] [Abstract][Full Text] [Related]
11. Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
Yu C; He F; Qu Y; Zhang Q; Lv J; Zhang X; Xu A; Miao P; Wu J
Bioorg Med Chem; 2018 May; 26(8):1859-1868. PubMed ID: 29500131
[TBL] [Abstract][Full Text] [Related]
12. Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
Marson CM; Matthews CJ; Atkinson SJ; Lamadema N; Thomas NS
J Med Chem; 2015 Sep; 58(17):6803-18. PubMed ID: 26287310
[TBL] [Abstract][Full Text] [Related]
13. Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKCα-mediated AHR-HDAC interactions.
Tsai CH; Li CH; Liao PL; Chang YW; Cheng YW; Kang JJ
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118564. PubMed ID: 31672612
[TBL] [Abstract][Full Text] [Related]
14. Inside HDAC with HDAC inhibitors.
Bertrand P
Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
[TBL] [Abstract][Full Text] [Related]
15. Role of Natural Products in Modulating Histone Deacetylases in Cancer.
Merarchi M; Sethi G; Shanmugam MK; Fan L; Arfuso F; Ahn KS
Molecules; 2019 Mar; 24(6):. PubMed ID: 30884859
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
Zhou M; Ning C; Liu R; He Y; Yu N
Bioorg Med Chem Lett; 2013 Jun; 23(11):3200-3. PubMed ID: 23639537
[TBL] [Abstract][Full Text] [Related]
17. Environment-sensitive fluorescent inhibitors of histone deacetylase.
Zhou X; Dong G; Song T; Wang G; Li Z; Qin X; Du L; Li M
Bioorg Med Chem Lett; 2020 Jun; 30(11):127128. PubMed ID: 32247729
[TBL] [Abstract][Full Text] [Related]
18. Potent and Selective Non-hydroxamate Histone Deacetylase 8 Inhibitors.
Kleinschek A; Meyners C; Digiorgio E; Brancolini C; Meyer-Almes FJ
ChemMedChem; 2016 Dec; 11(23):2598-2606. PubMed ID: 27860422
[TBL] [Abstract][Full Text] [Related]
19. Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
Tian Y; Lv W; Li X; Wang C; Wang D; Wang PG; Jin J; Shen J
Bioorg Med Chem Lett; 2017 Jul; 27(13):2943-2945. PubMed ID: 28501514
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors in the treatment of hematological malignancies.
Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
